A Two-part, Randomized, Double-blind, Placebo-controlled, Single Dose Study of BCT197 for the Prevention of Acute Kidney Injury (AKI) in Patients Undergoing Elective Cardiac Surgery With Cardiopulmonary Bypass (CPB)
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Acumapimod (Primary)
- Indications Acute kidney injury
- Focus Therapeutic Use
- Sponsors Novartis
Most Recent Events
- 12 Oct 2014 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
- 14 Aug 2014 New trial record